Marker Therapeutics (MRKR) Price to Sales (2016 - 2025)

Marker Therapeutics (MRKR) has reported Price to Sales for 9 consecutive years, with 22.55 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Price to Sales rose 52.59% year-over-year to 22.55 in Q4 2025; TTM through Dec 2025 was 7.02, a 56.48% increase from a year earlier, with the FY2025 full-year figure at 7.02, up 38.96% from the prior year.
• Price to Sales was 22.55 for Q4 2025 at Marker Therapeutics, up from 12.05 in the prior quarter.
• Over five years, Price to Sales peaked at 155.09 in Q3 2023 and troughed at 2.5 in Q1 2023.
• A 4-year average of 32.01 and a median of 24.16 in 2024 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales sank 93.44% in 2023 and soared 1130.88% in 2024, its largest moves.
• Over 4 years, Price to Sales stood at 8.26 in 2022, then jumped by 1777.49% to 155.09 in 2023, then sank by 90.47% to 14.78 in 2024, then surged by 52.59% to 22.55 in 2025.
• The last three Price to Sales figures came in at 22.55 (Q4 2025), 12.05 (Q3 2025), and 20.08 (Q2 2025), per Business Quant data.